Purpose: The purposes of this work are to (a) investigate whether the use of autoplanning and multiple iterations improves quality of head and neck (HN) radiotherapy plans; (b) determine whether delivery methods such as step-and-shoot (SS) and volumetric modulated arc therapy (VMAT) impact plan quality; (c) report on the observations of plan quality predictions of a commercial feasibility tool.
| INTRODUCTION
Head and neck (HN) cancer is a technically challenging treatment site in radiation oncology due to the complex anatomy and numerous organs at risk (OARs) in close proximity to targets. Treatment planning techniques for HN cancer have advanced from the conventional three-field technique to intensity modulated radiation therapy (IMRT) over two decades. 1 To achieve adequate target coverage while protecting numerous OARs, IMRT plans for HN cancer require highly conformal dose distributions and a steep dose fall-off between the boundary of tumor volumes and sensitive structures. With limited clinical resources (time and manpower), a major challenge in HN IMRT planning is large variations in plan quality among treatment planners in part due to varied planning skills and limited planning time. [2] [3] [4] Many publications have identified variations in IMRT plan quality. Hunt et al. 5 quantified geometric factors that influenced dosimetric sparing of the parotid in IMRT plan for HN cancer in 2006.
Moore et al. 3 developed a model to predict the mean dose of an organ that overlaps with the planning target volume (PTV) and found that clinical implementation of this predictive model successfully reduced the plan variations. Wu. et al. 6 and Yuan et al. 7 built a knowledge-based model to predict best achievable plan quality thus reducing plan quality variations. Knowledge-based treatment planning, however, depends on the plan qualities that are used for model building and the specific clinical practice of how planning target volumes and prescription doses are defined and prescribed.
Allowing flexibility and patient-specific organ sparing prediction, a commercial product, PlanIQ Feasibility (Sun Nuclear Corp., Melbourne, FL), has been developed. The predicted dose volume histograms (DVHs) are based on energy-specific dose spread calculation, reflecting the characteristics of photon dose distribution in media. 8 Another approach to robust planning is to create many planning solutions (multicriteria optimization) for a single clinical case so that clinicians can make a decision based on the trade-off among the dose coverage of the tumor volume and protections of sensitive structures. 9 The automatic planning tool developed by the Pinnacle (Philips Radiation Oncology Systems, Fitchburg, WI) commercial treatment planning system is to mimic the manual processes of skilled planners by progressively and iteratively adjusting and adding planning objectives, which may mitigate the shortcoming of the gradient-based optimization. 10 In an ideal world, a planner would be equipped with all of these tools: a tool that can reliably predict achievable DVHs as initial inputs of the planning objectives, a tool that can automatically and progressively adjust planning objectives, and a tool that can offer multiple solutions based on different trade-offs.
The purposes of this study are to (a) investigate whether the use of automation and multiple iterations can improve quality of HN plans; (b) determine whether delivery methods such as step-andshoot (SS) and volumetric modulated arc therapy (VMAT) impact plan quality; (c) report on the observations of auto-plan qualities with respect to the prediction of the feasibility tool.
| MATERIALS AND METHODS

2.A | Patient selection
Twenty HN patients with various tumor sites and stages were retrospectively selected from an institutional review board approved registry. We purposely chose these patients to reflect various clinical scenarios. The first ten of the twenty patient plans were used for initial testing of the auto-planning model in Pinnacle. These patients were treated with nine-beam step-and-shoot IMRT plans for either definitive or postoperative intent. For definitive cases, the primary targets were prescribed to a dose of 70-72 Gy while the regional lymph nodes were prescribed to a dose of 54-58 Gy. For post-operative cases, the prescription doses to the primary tumor beds were 60-66 Gy. The details of the tumor locations, stages, and prescription doses for the second set of ten HN patients are listed in Table 1 .
2.B | HN planning goals
The general HN planning goals and plan acceptance criteria have been established in our department. The treatment goals were to deliver prescription doses to ≥95% of the high dose planning target volumes (HD_PTV) and ≥95% of the low dose planning target volumes (LD_PTV). The planning acceptance criteria for OARs are listed in For the purpose of this study, we created two HN specific techniques: one used the nine beam step-and-shoot delivery, and the other used two VMAT arc delivery. Both techniques used the same planning goals for normal structures. Since our institution uses multiple machines to treat HN patients and some treatment machines do not have VMAT delivery, planners still must choose a specific treatment machine after loading the HN specific planning technique.
For the nine-beam AP-SS, the direct machine parameter optimization (DMPO) was chosen and the two-arc AP-VMAT, the optimization type chosen was the "SmartArc" from the Pinnacle system with the dose calculation at every 4˚with a convolution and superposition algorithm. For each HN case selected for this study, three plans were created: one clinical plan, one AP-SS, and one AP-VMAT.
2.D | Plan evaluation
Plan quality was evaluated based on several dosimetric endpoints for
PTVs and critical structures -including dose volume coverage, maximum dose to 0.03 cc (D 0.03cc ), and mean dose (D mean ) -as well as the conformality index (CI), the homogeneity index (HI), and the total monitor units (MUs) per fraction. The CI 11 was defined as
where V Rx is the tissue volume covered by the prescription dose for the HD_PTV and V PTV is the volume of the HD_PTV. For the ideal case, CI = 1. The HI was defined as
where D max is the maximum dose of the plan and D Rx is the prescription dose for the HD_PTV. The total MUs per fraction were also used to assess the plan delivery efficiency.
T A B L E 2 Head and neck planning acceptance criteria. factor is defined as the feasibility factor, with higher feasibility associated with higher f. The estimation is based on a series of energyspecific dose spread calculations, independent of any particular beam arrangement. 8 For a specific patient, this estimated calculation is based on the heterogeneous dataset along with the geometric relationship between the targets and OARs while taking into account the high-(penumbra driven) and low (PDD and scatter-driven) gradient dose spreading. The predicted DVHs from PlanIQ can be used as the input of IMRT planning objectives or as a tool for quality assurance. In this paper, we use the predicted DVHs for the latter.
Organs Criteria
HD_PTV V Rx ≥ 95% LD_PTV V Rx ≥ 95%
2.F | Statistical analysis
One sided paired sign test was used to test the difference in medians of the dosimetric endpoints between the clinical plans and the corresponding AP-SS and AP-VMAT plans. 12 The test is conducted by subtracting the paired values from two groups and counting the positive (c+) or negative (c−) signs. Let c equal the smaller one of c+ and c−, and let N be the total number of unequal pairs. The P-value is given by the cumulative binomial distribution,
The one sided test was used under the null hypothesis -the AP-SS/AP-VMAT plans are not better than the clinical plans in compared items. Statistical significance is achieved when P < 0.05 to conclude that the AP-SS/AP-VMAT plans are better than the clinical plans.
The Spearman rank correlation coefficient is used to describe the monotonic association between the PlanIQ feasibility and AP-VMAT endpoints. 13 The correlation coefficient is given by the following equation,
where Δd i is the difference between the ranks for each pair, and N is the total number of pairs.
The correlation coefficients were interpreted as: very high correlation if r s > 0.9; high correlation if 0.7 < r s ≤ 0.9; moderate correlation if 0.5 < r s ≤ 0.7; low correlation if 0.3 < r s ≤ 0.5; negligible correlation if r s ≤ 0.3.
3 | RESULTS Figure 1 shows the median, interquartile range (IQR), minimum, and maximum values of the selected dosimetric endpoints, HI, CI, and MU for the second set of ten HN patients. All AP-SS plans and AP-VMAT plans met the clinical dose limit requirements. As shown in show that for lung stereotactic body radiotherapy auto-planning reduces optimization time by 77.3% and total monetary cost by 3.6%. 14 As reported by Creemers et al., auto-planning requires roughly the same total planning time compared to manual planning, but it reduces the planners' "hands-on-time" by 75%.
15
The auto-planning module has some limitations. The beam arrangement must be initially set and cannot be changed during auto-planning. Auto-planning runs six optimization iterations, which may be excessive for simple cases. Though auto-planning techniques used in this study generated clinically acceptable plans for all ten HN patients without further modification, other patient cases may still require manual adjustments to achieve optimal results.
In this work, nonparametric statistical tests such as sign test and Spearman rank correlation are used due to the small sample size.
One must cautiously interpret the results as they are not as powerful as parametric tests such as t-test and Pearson correlation. We study plans with two prescription dose levels to maintain the data homogeneity. However, three dose level HN plans are also common at other institutions while our institution has adopted to two dose levels for most patients with HN cancer. With more prescription levels, the geometric and dosimetric relationships between targets and OARs will change, which may affect the auto-planning. Adjustment in the auto-planning technique is needed to accommodate such prescription changes even for the same disease site.
Auto-planning, among other methods such as knowledge-based planning and multicriteria optimization, is one of the advanced planning techniques to improve planning consistency and efficiency. HN cancer is one of the most challenging sites for treatment planning, and Pinnacle auto-planning is confirmed as a viable solution in an early study. 16 Other sites, such as prostate, 17 esophagus, 18 lung, 14, 15 and brain, 19 are also investigated by different groups. All studies have confirmed that auto-planning generates clinically acceptable T A B L E 4 Plan quality endpoints of the Clinical, AP_SS and AP_VMAT plans. One sided paired sign tests were performed between the Clinical and AP_SS, and between the Clinical and AP_VMAT. Results with P < 0.05 indicated statistical significance and were labeled with "*". plans. While auto-planning is a potential solution to achieve good plan quality and standardization, an independent plan quality check tool is necessary. Combining knowledge-based plan quality check and auto-planning is one solution. Using a model trained with prostate plans, Janssen et al. 20 demonstrate that knowledge-based prediction detects 25% of the examined auto-plans as suboptimal.
Another solution, as discussed in this study, is to use a patient-specific and anatomy-driven DVH prediction tool. The latter has the advantage of not being dependent on past planning experience.
The PlanIQ predictions are performed independently to help evaluate plan quality in this study. PlanIQ may also be used before treatment planning to help guide the planning process. Fried et al.
show that with the knowledge of PlanIQ predictions before HN planning, significant reduction in doses to contralateral parotid and larynx is achieved. to the parotids has a range, the AP-VMAT plans mostly cluster around 25 Gy, which is reflective to the clinical requirements (Table 2 ) and auto-planning technique (Table 3) 
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